Study Design
We performed a randomized double-blind, placebo controlled study of benralizumab in patients with severe CRSwNP refractory to standard treatment, that minimally included the use of nasal steroids and at least one prior polypectomy. Subjects were instructed to abstain from taking oral or nasal corticosteroids and antihistamines for a period of one month before screening. Subjects meeting criteria for entry were randomized to receive benralizumab 30mg SC or placebo according to the schedule illustrated in Figure 1. During the study, subjects with inadequate control of symptoms were offered nasal steroids and/or oral corticosteroids according to a predetermined rescue protocol.